- Home
- VRTX vs BE Comparison
VRTX vs BE Comparison
Compare VRTX & BE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VRTX | BE |
|---|---|---|
| Founded | 1989 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Industrial Machinery/Components |
| Sector | Technology | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7B | 86.0B |
| IPO Year | 2006 | 2018 |
Fundamental Metrics
Financial Performance| Metric | VRTX | BE |
|---|---|---|
| Price | $444.64 | $260.42 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 29 | 21 |
| Target Price | ★ $539.69 | $177.67 |
| AVG Volume (30 Days) | 1.1M | ★ 8.2M |
| Earning Date | 05-04-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 836.54 | N/A |
| EPS | ★ 4.02 | 0.23 |
| Revenue | ★ $2,488,652,000.00 | $2,023,994,000.00 |
| Revenue This Year | $10.79 | $64.67 |
| Revenue Next Year | $10.47 | $60.22 |
| P/E Ratio | ★ $110.02 | $1,258.87 |
| Revenue Growth | ★ 46.20 | 37.33 |
| 52 Week Low | $362.50 | $20.93 |
| 52 Week High | $509.98 | $322.83 |
Technical Indicators
Market Signals| Indicator | VRTX | BE |
|---|---|---|
| Relative Strength Index (RSI) | 56.43 | 44.88 |
| Support Level | $429.02 | $235.63 |
| Resistance Level | $461.66 | $312.91 |
| Average True Range (ATR) | 10.08 | 22.94 |
| MACD | 0.78 | -5.96 |
| Stochastic Oscillator | 83.11 | 16.05 |
Price Performance
Historical ComparisonAbout VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
About BE Bloom Energy Corporation
Bloom Energy designs, manufactures, sells, and installs solid oxide fuel cell systems for on-site power generation. Bloom Energy Servers are fuel-flexible and can use natural gas, biogas, and hydrogen to create 24/7 electricity for stationary applications. Bloom sells its systems in the United States and internationally.